Pharmacokinetics and dosage planning of cefozopran in patients with renal insufficiency

Tadasu Takenaka, Toyohiko Watanabe, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Tetsuzou Kaneshige, Hiroyuki Ohmori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We investigated pharmacokinetics of cefozopran (CZOP), a new cephem antibiotic, in patients with renal insufficiency. Serum levels of CZOP after a single administration were assayed by HPLC and urinary levels by Bioassay. 1) 1.0g CZOP were administered to healthy volunteers and patients with varying degrees of impaired renal function by 30minutes drip infusion. Pharmacokinetic parameters were determined using a two-compartment model. In healthy volunteers, the mean values of T1/2 (β) was 2.20h and β was 0.321/h. As proceeded the renal insufficiency, T1/2 (β) was prolonged and β was decreased. The mean urinary excretion rate within 24h was 70.0% in healthy volunteers and decreased to 32.5% in Patients with severe renal insufficiency whose creatinine clearrance (Ccr) were below 30ml/min. 2) To plan a regimen, β was selected as the parameter which varied in accordance with the degree of impaired renal function as measured by Ccr. A recommended dosing regimen in patients with renal insufficiency was studied.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalCHEMOTHERAPY
Volume41
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Pharmacokinetics and dosage planning of cefozopran in patients with renal insufficiency'. Together they form a unique fingerprint.

  • Cite this

    Takenaka, T., Watanabe, T., Hayashi, T., Hata, K., Ono, N., Kumon, H., Ohmori, H., Nanba, K., Kaneshige, T., & Ohmori, H. (1993). Pharmacokinetics and dosage planning of cefozopran in patients with renal insufficiency. CHEMOTHERAPY, 41, 147-153. https://doi.org/10.11250/chemotherapy1953.41.Supplement4_147